is a first in class, potent, selective and orally bioavailable Ataxia telangiectasia mutated (ATM) inhibitor

Preclinical pharmacology

ATM inhibitor AZD0156 exhibits activity in combination with agents such as chemotherapies and irradiation which induce DSBs. Through inhibiting repair of DSBs this generates an exploitable DDR dependency through an alternate pathway; AZD0156 therefore shows synergy with DDR inhibitors that result in DNA breaks e.g. Olaparib.

Suitable for

pre-clinical oncology studies (proposals)

Additional Information

Clinical Trials for this compound

See all of the Clinical Trials currently associated with this compound:

Publications for this compound

Journal of Medicinal Chemistry, Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase

 Gene information from the NCB

This compound works on the following gene: